Correlation Research Study: IQ2, NcIQ and IQ101 (NMT-CT)
Primary Purpose
Heart Failure, Dyspnea, Hypertension
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Noninvasive Hemodynamic Patient Monitor
Sponsored by
About this trial
This is an interventional diagnostic trial for Heart Failure focused on measuring Noninvasive, Hemodynamic, Monitoring, Critical Care, Swan-Ganz
Eligibility Criteria
Inclusion criteria:
- Age - 18-80 years
- Weight - 80-300 pounds
- Height - 5.0 feet - 6feet 4 inches Exclusion Criteria
- Ongoing medical emergency or acute medical illness
- NcIQ or ECG electrode adhesive allergy or sensitivity
Sites / Locations
Outcomes
Primary Outcome Measures
A direct correlation between output parameters of IQ2/NcIQ to IQ101
Secondary Outcome Measures
Full Information
NCT ID
NCT00491777
First Posted
June 22, 2007
Last Updated
June 22, 2007
Sponsor
Noninvasive Medical Technologies, Inc.
Collaborators
University of Florida, Shand's Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00491777
Brief Title
Correlation Research Study: IQ2, NcIQ and IQ101
Acronym
NMT-CT
Official Title
Correlation Study of NMT's IQ2, NcIQ and Its' Predicate Technology, IQ101.
Study Type
Interventional
2. Study Status
Record Verification Date
June 2007
Overall Recruitment Status
Completed
Study Start Date
June 2007 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
June 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Noninvasive Medical Technologies, Inc.
Collaborators
University of Florida, Shand's Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The new NcIQ thoracic impedance monitor is based on the predicate device, the IQ101. The new model uses the same 3-dimensional signal averaging as the original device, but also include second radio frequency signal to permit the device to work "wirelessly", i.e., without electrode lead attachments to the patient. This study seeks to 1) validate the use of the new device and confirm the correlation of the IQ101 and NcIQ. 2) Evaluate the ease of the new device.
The new IQ2 thoracic impedance monitor is based on the predicate device, the IQ101. The new model uses the same 3-dimensional signal averaging as the original device, but with smaller housing and updated operating software. This study seeks to 1) Validate the use of the new device and confirm the correlation of the IQ101 and IQ2. 2) Compare the ease of the devices.
Detailed Description
The IQ101 is the first generation of the non invasive cardiograph. This device uses impedance to a micro-electric field passing from the electrodes. The NcIQ uses Radio frequencies and the same 3 dimensional signal averaging algorithm used in the IQ101 to generate hemodynamic data. The radio waves enables the device to work without the contact lead arrays used in the IQ2 and can take measurements without even contacting the patient, hence can be applied through clothing and is simple to apply. This makes the potential use by first responders a possibility. The device measures the change in the radio wave reflection during the cardiac cycle to estimate ardiac function. Specifically, it measures cardiac output, the amount of blood pumped per minute, and other hemodynamic parameters previously only measurable with invasive catheters. The data us used to generate a LIFESCORE and can measure and report dangerous trends to the caretaker. The device has a companion device to download the data for the hospital providers to create a seamless transfer of care. The new device uses technology similar to the previous generation machine but has been miniaturized, given updated operating system, and newer computer technology that helped make the device smaller, and faster. The underlying patented algorithm was not changed. Therefore, it is expected to provide the same degree of accuracy and precision as the predicate device.
The IQ101 is the first generation of the non invasive cardiograph. This device uses impedance to a micro-electric field passing from the electrodes. The device can use the impedance and the change in the impedance during the cardiac cycle to estimate thoracic fluid volumes and cardiac function. Specifically, it measures cardiac output, the amount of blood pumped per minute, and other hemodynamic parameters previously only measurable with invasive catheters. There are many studies documenting the device's performance. The new device uses the same technology but has been modernized with updated operating system, and newer computer technology that helped make the device smaller, and faster. The device has also been redesigned to make operator use simpler and reduce the number wires involved. The underlying patented algorithm was not changed. Therefore, it is expected to provide the same degree of accuracy and precision as the predicate device with simplified user interface and lighter, smaller, more portable housing to improve ease of use.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure, Dyspnea, Hypertension, Pacemaker, Trauma
Keywords
Noninvasive, Hemodynamic, Monitoring, Critical Care, Swan-Ganz
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
25 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
Noninvasive Hemodynamic Patient Monitor
Primary Outcome Measure Information:
Title
A direct correlation between output parameters of IQ2/NcIQ to IQ101
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria:
Age - 18-80 years
Weight - 80-300 pounds
Height - 5.0 feet - 6feet 4 inches Exclusion Criteria
Ongoing medical emergency or acute medical illness
NcIQ or ECG electrode adhesive allergy or sensitivity
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kevin Ferguson, MD
Organizational Affiliation
Shand's Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Joseph A Tyndall, MD
Organizational Affiliation
Shand's Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
David Seaberg, MD
Organizational Affiliation
Shand's Hospital
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Correlation Research Study: IQ2, NcIQ and IQ101
We'll reach out to this number within 24 hrs